Usage Examples
- We have the Written Request; the gating item is getting the study reports in more than fifteen months before the NCE period expires.
- Pediatric exclusivity would push the approval bar six months past patent expiry, which is why legal wants the reports filed this quarter.
- FDA declined to issue a Written Request, so there is no pediatric exclusivity path for this product.
What is Pediatric Exclusivity?
Pediatric exclusivity is a six-month extension of a drug's existing FDA exclusivity and patent-based approval bars, earned by completing the pediatric studies FDA specified in a Written Request under FD&C Act section 505A.
Pediatric exclusivity exists because children were, for decades, dosed with drugs studied only in adults. Congress judged that mandates alone would not produce usable pediatric data fast enough, so it attached money to the problem: complete the pediatric studies FDA asks for, and the drug's protected period runs six months longer. Sponsors weigh a finite study cost against six additional months of unchallenged sales.
Pediatric exclusivity covers only the studies that are the subject of an FDA Written Request. Work done outside that document earns nothing, no matter how good the science. It also only extends protection that already exists, so a product with no remaining exclusivity period and no patent-based approval bar gains nothing at all. Pediatric exclusivity is not a marketing authorization, and it does not discharge PREA obligations.
Pediatric exclusivity is worked backwards from a date, not forwards from a study. Teams identify the protection they want extended, subtract FDA's 180-day window to accept or reject the reports, subtract the nine-month statutory cutoff, and set the reporting deadline from there. Written Request negotiation, study conduct, and report assembly all subordinate to that date; missing it forfeits the six months outright.
Not to be confused with
- PREA pediatric assessments
- PREA makes pediatric studies a condition of certain applications; the sponsor cannot decline. Pediatric exclusivity is voluntary and rewards completion, so the same study can be compulsory under PREA and still earn nothing unless FDA issued a Written Request for it.
- Patent term extension
- patent term extension lengthens the patent itself. Pediatric exclusivity never touches the patent; it extends the period during which FDA may not approve a competing application to six months after the patent expires.
- Orphan drug exclusivity
- orphan exclusivity is a standalone marketing bar granted at approval for a designated rare-disease use. Pediatric exclusivity creates no bar of its own; it lengthens whichever bars are already running.
- Paediatric Investigation Plan (PIP)
- a PIP is the EU pediatric obligation agreed with EMA. Completing a PIP produces no US pediatric exclusivity; only completion of studies subject to an FDA Written Request does.
Qualifying is a sequencing problem more than a scientific one. The statutory anchors:
What you must do
- 1Obtain a Written Request from FDA before relying on any study for exclusivity, because exclusivity is granted only for studies that are the subject of a written request21 U.S.C. 355a(h)
- 2Respond to the Written Request within 180 days of receipt, stating agreement and study timing, and address the request to propose pediatric labeling21 U.S.C. 355a(d)(1)
- 3Submit the completed study reports and budget for FDA taking up to 180 days to accept or reject them and notify the sponsor21 U.S.C. 355a(d)(4)
- 4Sequence the submission so FDA's determination is made more than 9 months before the exclusivity or patent period you intend to extend expires21 U.S.C. 355a(b)(2)
- 5Apply the six months to the right protections: statutory exclusivity periods run six months longer, and patent-based approval bars extend to six months after patent expiry21 U.S.C. 355a(b)(1)
Common mistakes
Running the pediatric studies before FDA issues the Written Request
exclusivity attaches only to studies that are the subject of a written request. Studies designed and completed ahead of the request, or drifting outside its terms, earn the full study cost and zero exclusivity.
Submitting the reports too late to matter
the extension is blocked if FDA's determination lands later than nine months before the period expires, and FDA has up to 180 days to make it. A reports package filed inside roughly fifteen months of expiry has no margin; a perfect study submitted late is worth nothing.
Assuming a completed PREA assessment converts into exclusivity
a Written Request may consist of studies already required under section 355c, but the request has to exist. Without it, the mandatory assessment is a condition of approval and produces no additional six months.
When This Matters
- We have the Written Request; the gating item is getting the study reports in more than fifteen months before the NCE period expires.
- Pediatric exclusivity would push the approval bar six months past patent expiry, which is why legal wants the reports filed this quarter.
- FDA declined to issue a Written Request, so there is no pediatric exclusivity path for this product.
Frequently Asked Questions
PREA makes pediatric assessments a mandatory part of certain applications, while pediatric exclusivity is a voluntary six-month reward for completing studies FDA specified in a Written Request. The two can overlap: a Written Request may consist of studies already required under PREA, but the written request itself is what creates the exclusivity.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
